In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be specified as "include-on" therapy. In Section C, https://abbv-744-and-its-impact-o02357.actoblog.com/32542468/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers